Key Highlights
- ZeroStack (ZSTK), formerly Flora Growth, secured up to US$14.7M in German pharmaceutical purchase orders via subsidiary Phatebo in July 2026.
- The company's balance sheet is dominated by a US$107M position in the 0G decentralized-AI token, which drove a US$36.7M Q1 net loss.
- Heavy dilution, thin cash of US$2.3M and going-concern framing make ZSTK a high-risk, speculative situation.
- The risks here are substantial and, in several cases, existential.
Why ZeroStack Is in Focus
ZeroStack Corp. (NASDAQ:ZSTK) is attempting one of the more unusual pivots on the small-cap market: a decade-old European pharmaceutical distributor bolted onto a crypto-heavy 'AI-focused asset management' strategy. In July 2026 the company said it had secured purchase orders worth up to US$14.7 million from two German pharmaceutical customers, even as its balance sheet reels from digital-asset losses. For ZSTK investors, the question is whether real distribution revenue can offset the volatility of a token-based treasury. In effect, the company is asking the market to value two very different businesses at once: one measured in shipped medicines, the other in the daily price of a single token.
What has happened?
At last closing, ZeroStack announced that its wholly owned German subsidiary, Phatebo GmbH, had received purchase orders totaling up to US$14.7 million (EUR 12.9 million) from two unnamed pharmaceutical companies for distribution in Germany. That followed a US$6.5 million order disclosed in March. Management cautioned that fulfilment depends on securing inventory financing from specialty lenders, with no guarantee such funding will be available on acceptable terms. Separately, in April the company committed to a US$107 million position in the '0G' decentralized-AI token ecosystem, exchanging a convertible note for roughly 142 million tokens through a Texas subsidiary and pledging to redomicile from Ontario to Texas.
Why the development matters
The two announcements capture ZSTK's split personality. Phatebo is a real, revenue-generating business with more than ten years of European logistics and regulatory experience, and the orders signal continued customer demand. That matters because it gives the company an operating anchor that most crypto-treasury shells lack, and it is the part of the story that could lend the pivot more credibility than a purely speculative token play.
But the pharmaceutical orders are dwarfed, financially, by the swings in the company's token holdings. A single quarter's change in the fair value of digital assets erased far more than the distribution business earns, making ZSTK's reported results a function of crypto prices rather than drug logistics.
Company and business overview
ZeroStack Corp. is the former Flora Growth Corp., a cannabis company that rebranded and began trading under the ZSTK ticker in early 2026 after pivoting toward digital assets. It now describes itself as 'the first Nasdaq-listed, AI-focused asset management company,' led by CEO Daniel Reis-Faria.
Its operating core is Phatebo GmbH, a wholly owned German pharmaceutical distributor and the group's largest revenue contributor, supplying products across an established European network. Layered on top is a treasury strategy centered on the 0G protocol, a decentralized-AI blockchain, in which ZeroStack aims to hold roughly 21% of total token supply and earn staking rewards. The combination is deliberately unusual.
Financial position and funding runway
ZeroStack's finances are dominated by crypto volatility. For the first quarter of 2026 the company reported revenue of about US$7.3 million but a net loss of US$36.7 million, driven by a US$60.7 million loss from changes in the fair value of digital assets. Trailing-twelve-month net loss ran to roughly US$120 million.
Digital assets of US$38.4 million made up about 85% of total assets, while cash was just US$2.3 million. Total assets had fallen from US$130.2 million at year-end to US$45.2 million. The 10-Q carries going-concern framing, with management leaning on staking rewards for liquidity. The contrast between roughly US$7.3 million of quarterly revenue and a US$60.7 million swing in the value of digital assets underscores how far the treasury now overshadows the underlying operating business.
Potential growth catalysts
Several developments could support the ZSTK story if they play out.
- Pharmaceutical orders: up to US$14.7 million in new German purchase orders, plus the earlier US$6.5 million order, point to recurring distribution demand through Phatebo.
- Debt elimination: the April transaction extinguished the company's convertible note, leaving ZeroStack describing itself as debt-free.
- Staking income: the 0G token position is intended to generate staking rewards, reported at around 22% APY, as a recurring source of liquidity.
- Texas redomicile: the planned move and corporate restructuring are pitched as simplifying the treasury strategy and giving public investors direct exposure to decentralized-AI infrastructure.
Principal risks investors should understand
The risks here are substantial and, in several cases, existential.
- Crypto concentration: with digital assets near 85% of the balance sheet, ZSTK's results and solvency track the price of a single, thinly traded token.
- Going concern and liquidity: cash of roughly US$2.3 million against heavy losses leaves the company dependent on token values and staking income holding up.
- Dilution: shares outstanding ballooned from about 1.0 billion to 2.4 billion after 1.37 billion pre-funded warrants were exercised in Q1 2026.
- Reverse-split and delisting history: the predecessor executed a 1-for-39 reverse split in August 2025 to keep its Nasdaq listing.
- Financing dependence: the pharmaceutical orders cannot be filled without securing inventory financing that is not assured.
What to monitor next
Investors weighing ZSTK should track a handful of concrete signals.
- Whether Phatebo secures the inventory financing needed to fulfil the German orders, and how much converts to revenue.
- The price and staking yield of the 0G token, given its outsized weight in assets.
- Completion of the Texas redomicile and the token-for-shares exchange.
- Cash burn and any new equity raises or further dilution.
- Nasdaq listing status and any further bid-price or compliance notices.
Conclusion
ZeroStack Corp. (NASDAQ: ZSTK) offers a genuinely rare mix: an established European pharmaceutical distributor strapped to a highly volatile, crypto-based AI treasury. The new German orders are real and encouraging, and the elimination of debt removes one overhang. Yet the numbers make clear that, for now, the token position drives the income statement and the going-concern risk. Whether the strategy delivers depends on Phatebo scaling steadily while the 0G bet avoids another destructive drawdown. On balance, the pharmaceutical arm looks like the steadier half of the story, while the token position supplies both the upside case and the principal threat to the company's survival. Until then, ZSTK remains a speculative, high-risk situation.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...